MX2022010258A - Composiciones y métodos para tratar la lesión renal. - Google Patents
Composiciones y métodos para tratar la lesión renal.Info
- Publication number
- MX2022010258A MX2022010258A MX2022010258A MX2022010258A MX2022010258A MX 2022010258 A MX2022010258 A MX 2022010258A MX 2022010258 A MX2022010258 A MX 2022010258A MX 2022010258 A MX2022010258 A MX 2022010258A MX 2022010258 A MX2022010258 A MX 2022010258A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating renal
- renal injury
- treating
- Prior art date
Links
- 206010061481 Renal injury Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 abstract 2
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 abstract 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979813P | 2020-02-21 | 2020-02-21 | |
| PCT/US2021/019084 WO2021168430A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods for treating renal injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010258A true MX2022010258A (es) | 2023-01-24 |
Family
ID=77391654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010258A MX2022010258A (es) | 2020-02-21 | 2021-02-22 | Composiciones y métodos para tratar la lesión renal. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4106748A4 (https=) |
| JP (1) | JP2023515081A (https=) |
| KR (1) | KR20230011910A (https=) |
| AU (1) | AU2021224268A1 (https=) |
| CA (1) | CA3168728A1 (https=) |
| MX (1) | MX2022010258A (https=) |
| WO (1) | WO2021168430A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| JP2020514323A (ja) | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
| KR102921276B1 (ko) | 2018-11-21 | 2026-02-03 | 케이스 웨스턴 리저브 유니버시티 | 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법 |
| TW202419452A (zh) * | 2022-11-11 | 2024-05-16 | 大陸商賽諾哈勃藥業（成都）有限公司 | 調控１５－ｐｇｄｈ活性的化合物、其藥物組合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2838533T3 (da) * | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| AU2014342811B2 (en) * | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN107921025A (zh) * | 2015-03-08 | 2018-04-17 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| AU2016248080A1 (en) * | 2015-04-14 | 2017-11-02 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| JP7426941B2 (ja) * | 2018-04-04 | 2024-02-02 | ケース ウエスタン リザーブ ユニバーシティ | 腎傷害を治療するための組成物および方法 |
-
2021
- 2021-02-22 JP JP2022549924A patent/JP2023515081A/ja active Pending
- 2021-02-22 KR KR1020227032520A patent/KR20230011910A/ko not_active Withdrawn
- 2021-02-22 CA CA3168728A patent/CA3168728A1/en active Pending
- 2021-02-22 EP EP21756279.2A patent/EP4106748A4/en not_active Withdrawn
- 2021-02-22 WO PCT/US2021/019084 patent/WO2021168430A1/en not_active Ceased
- 2021-02-22 MX MX2022010258A patent/MX2022010258A/es unknown
- 2021-02-22 AU AU2021224268A patent/AU2021224268A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4106748A4 (en) | 2024-02-28 |
| KR20230011910A (ko) | 2023-01-25 |
| CA3168728A1 (en) | 2021-08-26 |
| EP4106748A1 (en) | 2022-12-28 |
| JP2023515081A (ja) | 2023-04-12 |
| WO2021168430A1 (en) | 2021-08-26 |
| AU2021224268A1 (en) | 2022-09-15 |
| US20230052363A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MA48772B1 (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| CR20240296A (es) | Inhibidores parp1 | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| WO2020058979A3 (en) | Methods of treating amyotrophic lateral sclerosis | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| NZ749997A (en) | Combination of a pd-l antagonist and a raf inhibitor for treating cancer | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2024003967A (es) | Resmetirom para reducir el volumen del higado. | |
| MX2023005530A (es) | Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon. | |
| AR122933A1 (es) | Métodos para tratar la enfermedad cardiovascular | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| MX2021006210A (es) | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. |